Abstract 299P
Background
Nasopharyngeal cancer is the most common head and neck cancer in Indonesia with prevalence of 28.4% among all adult head and neck cancer. Radiotherapy and chemotherapy are the main modalities for nasopharyngeal cancer treatment, With proper treatment, patients with nasopharyngeal cancer would have 5-year survival rate of above 80%, even in locally advanced nasopharyngeal cancer. However toxicity associated with nasopharyngeal cancer treatment is quite burdensome for the patients especially toxicity in terms of hematology, mucositis, nausea, and vomiting. Due to the burdening toxicity of chemoradiation treatment for the patients, several chemotherapy schedules were attempted. We aimed to search and elucidate high quality evidence available to date to answer our clinical question, whether triweekly or weekly concurrent chemoradiation is better for nasopharyngeal cancer treatment in terms of survival.
Methods
Literature searching was conducted on 3 databases: PubMed, EBSCOhost, and Scopus using keyword “Nasopharyngeal Cancer”, “Weekly Chemotherapy”, “Triweekly Chemotherapy”, “Overall Survival” and its synonyms using both MeSH and non-MeSH terms. Critical Appraisal for selected studies was done by 3 different person, using CEBM Critical Appraisals Tools.
Results
Six studies were selected to be relevant after elaborate search, which was then critically apprasied and found to be valid. Results from all those 6 studies found that weekly vs. triweekly chemoradiation regimen leads to similar survival outcome in nasopharyngeal cancer patients. Overall Survival (OS) rates from those 6 studies showed comparable result among both regimens (3-Year OS, 91% vs 90.8%; 5-year OS, 89% vs. 91%, 85.6% vs 90%, 78.9% vs 85.2%) and, all OS rate outcomes didn’t reach significant difference for all 6 studies.
Conclusions
Weekly and triweekly chemoradiation regimens for nasopharyngeal cancer were shown to be similar in terms of overall survival. The choice of weekly or triweekly chemoradiation for nasopharyngeal cancer patient should tailored according to institutional condition and capability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract